Welcome to our dedicated page for Cooper news (Ticker: COO), a resource for investors and traders seeking the latest updates and insights on Cooper stock.
CooperCompanies (NYSE: COO) delivers essential updates from the forefront of medical device innovation through its CooperVision and CooperSurgical divisions. This hub provides investors and healthcare professionals with direct access to official announcements, including product developments, regulatory milestones, and strategic initiatives shaping the vision care and women's health sectors.
Find curated press releases covering earnings results, clinical trial updates, and market expansion activities. Track innovations in silicone hydrogel contact lenses and fertility treatment technologies alongside analysis of industry trends impacting COO's global operations. Our repository simplifies monitoring of key developments across 130+ countries where Cooper's life-enhancing devices serve patients and providers.
Bookmark this page for real-time updates on FDA clearances, acquisition activity, and leadership changes. Subscribe to alerts for breaking news about COO's specialty lens portfolio and reproductive health solutions maintaining its position as a medical technology leader.
CooperCompanies (NYSE: COO) will participate in the Oppenheimer 31st Annual Healthcare Conference on March 17, 2021. The session, representing CooperVision, will be led by Executive Vice President and COO Daniel McBride at 1:10 PM ET. Investors can access a live webcast through CooperCompanies' Investor Relations webpage, with an archived audio replay available later that day. CooperCompanies operates globally, focusing on vision care and women's health through its divisions, CooperVision and CooperSurgical, with a workforce exceeding 12,000.
CooperCompanies (NYSE: COO) will announce its first quarter 2021 financial results on March 4, 2021, at 4:15 PM ET. Following the announcement, a conference call will take place at 5:00 PM ET to discuss the financial results and recent developments. The conference call can be accessed by dialing 855-643-4430 in the U.S. or 707-294-1332 internationally, with the passcode 'Cooper'. A replay of the call will be available until March 11, 2021. CooperCompanies operates in vision care and women's health, with a global workforce exceeding 12,000.
EssilorLuxottica and CooperCompanies have announced a joint venture to acquire SightGlass Vision, a U.S. company innovating spectacle lenses to combat myopia progression in children. This 50/50 venture aims to leverage both companies' expertise to enhance the commercialization of SightGlass Vision's lenses, complementing existing products like Essilor's Stellest lens and CooperVision's MiSight. Myopia affects 2.6 billion globally, expected to rise to 5 billion by 2050, making this collaboration essential in addressing this eye health crisis.
CooperSurgical has acquired California-based AEGEA Medical, known for its FDA-approved Mara™ Water Vapor Ablation System. This strategic acquisition enhances CooperSurgical's portfolio in women's healthcare, focusing on in-office treatments for heavy menstrual bleeding. The Mara system offers a two-minute, effective solution, demonstrated by clinical trials to improve quality of life for patients. With 99% of users reporting improved well-being, the acquisition aligns with CooperSurgical's commitment to innovative healthcare solutions.
CooperCompanies Achieves Great Place to Work Certification
On January 26, 2021, CooperCompanies announced that it has been recognized as a Great Place to Work-Certified™ organization for the third consecutive year. Employees rated the company highly for attributes such as pride, camaraderie, and respect. Notably, 91% of employees felt welcomed upon joining. President Albert White emphasized the importance of a supportive culture, while Great Place to Work highlighted Cooper's commitment to a positive employee experience. Cooper operates in the medical device sector, focusing on vision care and women’s health.
CooperCompanies (NYSE: COO) has declared a semi-annual dividend of 3 cents per share, set to be paid on February 9, 2021, to stockholders recorded by January 22, 2021. This decision aligns with the company's strategy of providing annual dividends, reflecting its commitment to shareholder returns. Cooper operates through two main units: CooperVision and CooperSurgical, focusing on vision care and women's health, respectively. With over 12,000 employees and products available in over 100 countries, CooperCompanies continues to grow in the medical device industry.
CooperCompanies (NYSE: COO) will present virtually at the J.P. Morgan Healthcare Conference on January 12, 2021, at 12:40 PM PT (3:40 PM ET). Al White, President and CEO, will represent the company during the event. Investors can access the live webcast via the Investor Relations section of CooperCompanies' website, with a replay available 24 hours post-presentation. CooperCompanies operates through two units: CooperVision, focusing on vision care, and CooperSurgical, which advances health for women and families. The company is headquartered in San Ramon, California.
CooperCompanies (NYSE: COO) has announced its annual stockholder meeting scheduled for March 17, 2021. Stockholders on record as of January 21, 2021, will be eligible to vote on important matters, including the election of directors. The company operates through two divisions: CooperVision, focused on vision care and contact lenses, and CooperSurgical, which advances women's health, fertility, and genomics. With over 12,000 employees and sales in more than 100 countries, CooperCompanies maintains a robust global presence.
CooperCompanies (NYSE:COO) announced the retirement of A. Thomas Bender and Allan E. Rubenstein, M.D., who will not seek re-election at the March 2021 Annual Meeting of Stockholders. Bender, with Cooper since 1991, significantly restructured the company, driving growth and international expansion. Rubenstein, with 29 years of service, contributed to strategic and clinical enhancements. Both have played vital roles in shaping Cooper into a leading global medical device company, with over 12,000 employees and products in over 100 countries.
CooperCompanies (NYSE: COO) reported its fiscal fourth quarter and full year results for the period ending October 31, 2020. Revenue fell by 1% year-over-year to $681.6 million, with CooperVision down 1% to $506.3 million, and CooperSurgical down 4% to $175.3 million. GAAP diluted EPS was $1.64, a 32% decrease from the prior year. Non-GAAP diluted EPS also dropped 4% to $3.16. Despite these declines, the company reported taking market share in its contact lens and fertility sectors.